Amylyx(AMLX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $317 million in cash and marketable securities, down from $344 million at the end of Q3 2025, providing a cash runway into 2028 [16] - Total operating expenses for Q4 2025 were $36.6 million, an 8% decrease from the same period in 2024 [16] - Research and development expenses were $21.2 million compared to $22.9 million in Q4 2024, primarily due to decreased spending on AMX0035 for ALS and PSP [17] - Selling, general, and administrative expenses were $15.4 million, down from $17.1 million in Q4 2024, mainly due to reduced consulting and professional services [17] Business Line Data and Key Metrics Changes - The pivotal phase III LUCIDITY trial for avexitide was initiated in 2025, focusing on post-bariatric hypoglycemia (PBH) [5] - AMX0114 received Fast Track designation and showed a favorable safety profile in the phase 1 LUMINA trial for ALS, allowing progression to the next cohort [6][7] - The company is also advancing AMX0318, a long-acting GLP-1 receptor antagonist, as a development candidate for PBH and other rare diseases [6] Market Data and Key Metrics Changes - The estimated population of individuals living with PBH in the U.S. is approximately 160,000, based on studies of bariatric surgery outcomes [9] - The company is conducting extensive market research to understand the patient journey and treatment landscape for PBH, corroborating its prevalence estimates with clinics [36] Company Strategy and Development Direction - The company aims to deliver top-line data from the LUCIDITY trial in Q3 2026 and is preparing for a potential NDA submission and commercialization of avexitide in 2027 [7][8] - The broader pipeline strategy includes leveraging expertise in endocrine conditions and neurodegenerative diseases to build a diverse portfolio of potential medicines [20] - The company is actively building its commercial infrastructure and conducting market research to support the launch of avexitide [8][9] Management's Comments on Operating Environment and Future Outlook - Management emphasized the significant unmet need in PBH and the urgency of their work to potentially deliver the first approved therapy for this condition [5][19] - The company is optimistic about the upcoming pivotal trial results and the potential for avexitide to address a critical medical need [19][22] Other Important Information - The company is ramping up medical insights capabilities, disease education activities, and community engagement to prepare for the potential launch of avexitide [15] - The open-label extension of the LUCIDITY trial is already underway, allowing participants to continue receiving treatment after the double-blind phase [14] Q&A Session Summary Question: Learnings from the clinical trial execution - Management highlighted that the study design was informed by prior successful trials, and the unmet need for PBH is significant, with hypoglycemic events being medical emergencies [25][26] Question: Powering dynamics of the study - Management explained that they expect minimal placebo response based on previous trials and have designed the study to be well-powered [29][30] Question: Commercial preparations and market research - The company is conducting substantial commercial preparations, including literature assessments and discussions with key opinion leaders to understand the PBH market [34][36] Question: Enrollment in the open-label extension - Management confirmed that participants are rolling over into the open-label extension following the completion of recruitment for the LUCIDITY trial [39] Question: Current patient and physician experience with Acarbose - Management clarified that Acarbose is not FDA approved for PBH and is not well-tolerated, thus not expected to impact the uptake of avexitide [73][75] Question: ICD-10 code for PBH - Management discussed the significance of an ICD-10 code for PBH, which would enhance awareness and facilitate appropriate care for patients [78][80]